Biological therapy for psoriasis: Practical experience at a French dermatology unit;Utilisation des biothérapies dans le psoriasis modéré à sévère: Expérience du service de dermatologie du CHU de Besançon (2004-2008)

Annales de Dermatologie et de Venereologie

Volumn 136, Issue 12, 2009, Pages 877-882

  Saccomani, C ^a   Penz, S ^a   Guerre Schmidt, R ^a   Riou, M O ^a   Pelletier, F ^a   Puzenat, E ^a   Mermet, I ^a   Levang, J ^a   Humbert, P ^a,b   Aubin, F ^a,b  

^a UNIVERSITY HOSPITAL OF BESANÇON   (France)

^b UNIVERSITÉ DE FRANCHE COMTÉ   (France)

Author keywords

Biologics; Efalizumab; Etanercept; Infliximab; Psoriasis

Indexed keywords

EFALIZUMAB; ETANERCEPT; INFLIXIMAB;

ADULT; ARTHRALGIA; ARTICLE; ASTHENIA; BODY SURFACE; CLINICAL ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; CORONARY ARTERY THROMBOSIS; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; LUNG DISEASE; MALE; MYALGIA; PANCREAS CANCER; PRURITUS; PSORIASIS; QUALITY OF LIFE; RETROSPECTIVE STUDY; SKIN LUPUS ERYTHEMATOSUS; TREATMENT DURATION; TREATMENT FAILURE; URTICARIA;

ANTIBODIES, MONOCLONAL; COHORT STUDIES; DERMATOLOGIC AGENTS; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; SAFETY; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 73349097843     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.annder.2009.10.200     Document Type: Article

References (16)

1. A.K. Brimhall, L.N. King, J.C. Licciardone, H. Jacobe, and A. Menter Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials Br J Dermatol 159 2008 274 285 (Pubitemid 352009861)
2. R.B. Warren, B.C. Brown, D. Lavery, D.M. Ashcroft, and C.E. Griffiths Biologic therapies for psoriasis: practical experience in a U.K tertiary referral centre Br J Dermatol 160 2009 162 169
3. R.J. Driessen, M.A. Berends, J.B. Boezeman, P.C. van de Kerkhof, and E.M. de Jong Psoriasis treatment with etanercept and efalizumab: clinical strategies influencing treatment outcome Br J Dermatol 158 2008 1098 1106
4. K. Ahmad, and S. Rogers Two years of experience with Etanercept in recalcitrant psoriasis Br J Dermatol 156 2007 1010 1014 (Pubitemid 46642862)
5. A. Costanzo, K. Peris, M. Talamonti, A. Di Cesare, M.C. Fargnoli, and E. Botti Long-term treatment of plaque psoriasis with efalizumab: an Italian experience Br J Dermatol 156 Suppl. 2 2007 17 23 (Pubitemid 46434870)
6. C. Ferrándiz, and J.M. Carrascosa Managing moderate-to-severe psoriasis with efalizumab: experience at a single Spanish institute Br J Dermatol 156 Suppl. 2 2007 24 29 (Pubitemid 46434871)
7. C. Antoniou, I. Stefanaki, A. Stratigos, G. Avgerinou, P. Stavropoulos, and I. Potouridou The Greek experience with Efalizumab in psoriasis from a University Dermatologic Hospital Br J Dermatol 156 Suppl. 2 2007 12 16 (Pubitemid 46434869)
8. http://www.afssaps.sante.fr/ ou http://agmed.sante.gouv.fr/ htm/10/tnf/indtnf.htm pour le lien direct pour les « Recommandations nationales : prévention et prise en charge des tuberculoses survenant sous anti-TNFα » (juillet 2005).
9. A.B. Gottlieb, T. Hamilton, I. Caro, P. Kwon, P.G. Compton, C.L. Leonardi Efalizumab Study Group Long-term continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: updated results from an ongoing trial J Am Acad Dermatol 54 Suppl 1 2006 S154 S163
10. A.B. Gottlieb, R. Evans, S. Li, L.T. Dooley, C.A. Guzzo, and D. Baker Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial J Am Acad Dermatol 51 2004 534 542 (Pubitemid 39278071)
11. L.L. Lecluse, G. Piskin, J.R. Mekkes, J.D. Bos, and M.A. de Rie Review and expert opinion on prevention and treatment of infliximab-related infusion reactions Br J Dermatol 159 2008 527 536
12. K.B. Gordon, A.B. Gottlieb, C.L. Leonardi, B.E. Elewski, A. Wang, and A. Jahreis Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy J Dermatolog Treat 17 2006 9 17 (Pubitemid 43247302)
13. J.P. Ortonne, C.E. Griffiths, E. Daudén, R. Strohal, D. Robertson, R. Pedersen, et al. Efficacy and safety of continuous versus paused Etanercep treatment in patients with moderate-to-severe psoriasis over 54 weeks: The CRYSTEL Study Expert Review Dermatol 3 2008 657 665
14. R.J. Driessen, J.B. Boezeman, P.C. van de Kerkhof, and E.M. de Jong Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome Br J Dermatol 160 2009 670 675
15. M. Viguier, P. Richette, F. Aubin, M. Beylot-Barry, M. Lahfa, and C. Bedane Onset of psoriatic arthritis in patients treated with efalizumab for moderate to severe psoriasis Arthritis Rheum 58 2008 1796 1802 (Pubitemid 351847534)
16. A. Menter, S.R. Feldman, G.D. Weinstein, K. Papp, R. Evans, C. Guzzo, et al. A randomized comparison of continuous vs. intermittent Infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis J Am Acad Dermatol 56 2007 e1 e15